Spotlight Therapeutics, Inc.

Walking Fish Therapeutics has closed despite being on the precipice of entering the clinic. (Getty/zoom-zoom) Walking Fish Therapeutics has closed after a lead investor backed out of a critical series B round.  CEO Rusty Williams, M.D., Ph.D., said in an interview with Fierce Biotech that the company was on the precipice of securing fresh capital to enter the clinic when an unnamed top investor backed out, citing concerns about the cost of a multiyear lease. The decision, which came after Walking Fish secured two federal ARPA-H grants to help take the pressure off internal financiers, stunned Williams. “It was a shock,” the CEO said. “T​​his investor just pulled out abruptly and said they wanted to shut down the company.” As a result, 35 employees were laid off, which followed two other layoff rounds to help dwindle costs.  Endpoints News first reported Walking Fish’s closure.  Walking Fish was more than two years removed from a $73 million series A co-led by Northpond Ventures and First Spark Ventures. The biotech previously received funding from Illumina’s venture arm, Quan Capital and the Emerson Collective.  Less than a year ago, the company was adding to its leadership team, hiring Julie Kim as chief business officer and Nallakkan Arvindan, Ph.D., as chief technology officer. Kim joined from Quan after stints at Genentech and Roche, while Arvindan was the former CTO at Spotlight Therapeutics.  The financing and new hires were meant to help advance a three-asset portfolio of B-cell-based therapies, with a lead candidate designed to treat Fabry disease. That asset, WFX-001, was most recently in IND-enabling studies, according to Walking Fish’s website. The biotech intended to reconfigure B cells to help build proteins, including a deficient enzyme in patients with Fabry disease. The biotech also had two additional preclinical assets aimed at undisclosed targets. There’s “a fair amount of interest” in those assets, according to Williams, and conversations are ongoing to find a buyer.  Previously, Williams served as Five Prime Therapeutics' CEO for more than 15 years before its acquisition by Amgen. Before that, he was the chief scientific officer at Chiron, which ultimately was bought by Novartis for $5.1 billion. Now, he’s helming a new venture, Ten30 Bio, which is working on oral molecules.  Reflecting on Walking Fish’s work, Williams concedes that the cost of cell therapy manufacturing and associated clinical trial costs were difficult to overcome. It’s a painful conclusion that many others in cell therapy have realized as they pivot to treat autoimmune conditions.  “I think that B-cell therapy is likely to have its day; I think that what we were doing would have worked,” he said. “But it was just too expensive to get the phase 1 done in that financing environment.” 

DUBLIN, March 2, 2023 /PRNewswire/ -- The "Growth Opportunities In Gene Editing Technologies, Advanced RNA Therapeutics, Antibody Drug Conjugates and Biomanufacturing" report has been added to ResearchAndMarkets.com's offering. This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) highlights some of the recent innovations in gene editing technologies, which aim to make them more targeted and efficient. It also covers few innovations around ADCs (antibody drug conjugates) and its different components which are paving the way for development of safer and longer acting ADCs. In addition, advances in RNA therapeutics including small activating RNA and circular RNA based therapeutics and targeted delivery carriers have been covered. A PoC diagnostic to diagnose psoriasis and automation platform for egg and embryo management are also a part of this issue. The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Key Topics Covered: Innovations in Gene Editing Technologies, Advanced RNA Therapeutics, Antibody Drug Conjugates and Biomanufacturing Exploring the Potential of Circular Ribonucleic Acid (RNA) Therapeutics To Treat Rare Diseases Value Proposition of ORNA Therapeutics ORNA Therapeutics-Investor Dashboard Accelerated Clinical Development of Small Active RNAs to Treat Difficult to Target Diseases Value Proposition Mina Therapeutics Mina Therapeutics-Investor Dashboard Artificial Intelligence (AI)-based Platform Developing Biocompatible RNA Delivery System to Target Multiple Organs Value Proposition of Sixfold Bioscience Sixfold Bioscience-Investor Dashboard Engineered Ribonucleoprotein (RNP) for Delivery of Gene Editing Molecule Value Proposition of Spotlight Therapeutics Spotlight Therapeutics-Investor Dashboard Advanced Analytical Tools to for Cell Line Optimization and Development Valitacell-Value Proposition ValitaCell-Investor Dashboard AI Powered, Integrated Supply Chain Management Platform for Cell and Gene Therapies Trakcel's Proposition Trakcel-Investor Dashboard Novel Class of Site-Specific Nuclease for Development of Allogeneic CAR-T Cells Value Proposition of Poseida Therapeutics Poseida Therapeutics-Investor Dashboard Synthetic Enzyme based on Meganucleases For Developing Innovative Therapies Value Proposition of Precision Biosciences, Precision Biosciences-Investor Dashboard RNA Interference & TCR Inhibition technology for Generating Allogeneic CAR-T Cells Value Proposition of Celyad Oncology Celyad Oncology-Investor Dashboard Targeted Gene-editing Technology Using Short Guide RNA for the Development of Transformative Medicines Value Proposition of Editas Medicine Editas Medicine-Investor Dashboard Engineered Zinc Finger Nuclease Based Targeted Gene Editing Sangamo Therapeutics-Value Proposition Sangamo Therapeutics-Investor Dashboard Therapeutics Targeting Growth Factor Pathways to Treat Fibrotic Indications AgomAb Therapeutics-Value Proposition AgomAb Therapeutics-Investor Dashboard Microfluidics-based Platform for Differential Diagnosis of Psoriasis and Eczema Dermagnostix GmbH-Value Proposition Dermagnostix-Investor Dashboard Toolbox Approach to Developing ADC Technologies for Various Types of Oncologic Targets Iksuda Therapeutics' Value Proposition Iksuda Therapeutics-Investor Dashboard Plug-and-play Engineered Antibodies for Targeted Cancer and Viral Disease Therapeutics Xencor's Value Proposition Xencor-Investor Dashboard Streamlined and Automated Cryospecimen Management Platform for Frozen Eggs and Embryos for Infertility Treatment TMRW Life Sciences' Value Proposition TMRW Life Sciences-Investor Dashboard Digital Biomarkers for Drug Development Trials in the Pharmaceutical Industry VivoSense's Value Proposition VivoSense-Investor Dashboard Flexible, Scalable and Cost-efficient Peptide Based Linker Platform, Offering Highly Stable Antibody Drug Conjugates Value Proposition of Araris Biotech Araris biotech-Investor Dashboard Key Contacts 2. Appendix Criteria for Rating of Innovations--Explanation A selection of companies mentioned in this report includes AgomAb Therapeutics Araris biotech Celyad Oncology Dermagnostix Editas Medicine Iksuda Therapeutics Mina Therapeutics ORNA Therapeutics Poseida Therapeutics Precision Biosciences Sangamo Therapeutics Sixfold Bioscience Spotlight Therapeutics TMRW Life Sciences Trakcel ValitaCell VivoSense Xencor For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

点击这里，欣赏重磅直播！正文共： 5437字 31图预计阅读时间： 14分钟01前言2020年诺贝尔化学奖得主Emmanuelle Charpentier教授、Jennifer Doudna教授（图片来源：诺贝尔奖官网）2020年10月7日下午5时48分，备受关注的2020年诺贝尔化学奖获奖名单揭晓。法国微生物学家、遗传学家和生物化学家Emmanuelle Charpentier教授和美国生物学家Jennifer Doudna教授因其在开发基因组编辑技术方面的杰出贡献而荣获殊荣。两位获奖者将分享1000万瑞典克朗奖金（约合760万人民币）。Emmanuelle Charpentier教授和Jennifer A. Doudna教授发现了CRISPR/Cas9基因剪刀，基因技术中最犀利的工具之一。借助这个工具，研究人员可以非常高精度地改变动物、植物和微生物的DNA。这项技术对生命科学产生了革命性的影响，正在为新的癌症疗法做出贡献，并有望使治愈遗传性疾病的梦想成真。Charpentier教授和Doudna教授既是卓越的科学家，同时也是成功的连续创业家。目前，Charpentier教授创办或参与创办了两家生物技术公司，它们是CRISPR Therapeutics、ERS Genomics。ERS Genomics知识产权和企业发展副总裁Michael Arciero先生曾莅临药时代直播间，进行了精彩的演讲。CRISPR/Cas9技术在新药研发中的应用及相关专利布局｜药时代直播间第113期Jennifer A. Doudna教授则创办或参与创办了五家生物技术公司，分别是：Intellia Therapeutics、Editas Medicine、Mammoth Biosciences、Caribou Biosciences、Scribe Therapeutics。药时代的这篇报道文章受到朋友们的关注，阅读量1.2万+。股票大涨！今年的诺贝尔化学奖得主很年轻，既是杰出的科学家，也是成功的企业家！022022年诺奖得主：斯坦福大学Bertozzi教授2022年10月5日下午5点45分，瑞典皇家科学院宣布，美国科学家卡罗琳·贝尔托西 (Carolyn R. Bertozzi)、丹麦科学家摩顿·P·梅尔达尔 (Morten P. Meldal)、美国科学家卡尔·巴里·夏普利斯（K. Barry Sharpless）荣膺2022年诺贝尔化学奖，以表彰他们在点击化学和生物正交化学领域作出的杰出贡献。2022年诺贝尔化学奖得主Carolyn R. Bertozzi教授（左）、Morten Meldal教授（中）和K. Barry Sharpless教授（右）（图片来源：诺贝尔奖官网）其中，斯坦福大学Carolyn R. Bertozzi教授成为了诺奖百年历史上第八位女性诺贝尔化学奖得主。2022年新晋诺奖得主Carolyn R. Bertozzi教授（图片来源：网络）和Charpentier教授和Doudna教授一样，Bertozzi教授既是卓越的科学家，同时也是成功的连续创业家，创办了很多家企业。据《Medaverse》统计，Carolyn Bertozzi教授共同创立了Thios Pharmceuticals，Redwood Bioscience, Enable Biosciences, Palleon Pharmaceuticals, InterVenn Bio, OliLux Bio, Grace Science，Lycia Therapeutics和Shasqi。此外她还是多家公司的科学顾问，包括Spotlight Therapeutics、Ambagon Therapeutics等公司。（图片来源：网络）Bertozzi教授荣获诺奖的消息一公布，这些企业纷纷抢发新闻稿！~~03举几个例子！~~2020年7月，也就是在获得当年诺贝尔化学奖的三个月前，Bertozzi教授和她斯坦福大学的团队在Nature上发表了一篇重要的文章，《Lysosome-targeting chimaeras for degradation of extracellular proteins》，报道了她们设计的抗体。这种抗体不但可以与靶点蛋白相结合，而且与细胞表面受体的相互作用能够将靶点蛋白内化并且“拖到”细胞的溶酶体中，这些被拖进溶酶体的蛋白将被消化。Bertozzi教授称这种抗体为溶酶体靶向嵌合体（lysosome-targeting chimera，LYTAC）。Bertozzi教授作为学术创始人，联合创办了Lycia Therapeutics公司。2020年6月9日，生物技术公司Lycia Therapeutics浮出水面，创始投资人Versant Ventures投资5000万美元。2021年8月25日，Lycia公司与礼来公司达成多年研究合作和许可协议，重点是使用Lycia研发的LYTAC技术发现、开发和商业化新型靶向治疗药物。Lycia收到了3500万美元的首付款，将有资格获得超过16亿美元的潜在里程碑付款，以及上市后销售额从中位一位数到低位两位数的销售提成。2021年9月9日，Lycia Therapeutics宣布完成7000万美元的超额认购B轮融资。Redmile Group领投，创始投资人Versant Ventures和新投资者Cowen Healthcare Investments、Invus、RTW Investments、礼来公司以及Alexandria Venture Investments等跟投。目前，Lycia团队已经在实验中成功降解包括EGFR和PD-L1在内的膜蛋白，以及ApoE4在内的分泌蛋白。据《生物世界》报道，Carolyn Bertozzi教授于2015年创立了生物技术公司Palleon Pharmaceuticals，致力于开发糖介导的免疫调节治疗癌症和炎症性疾病，例如将唾液酸酶与PD-L1或HER2抗体形成融合蛋白，实现双管齐下的抗癌效果。目前，该公司已完成约1.5亿美元融资，其中靶向肿瘤细胞和免疫细胞上的免疫抑制性唾液聚糖的双功能唾液酸酶融合蛋白药物E-602已处于1/2期临床研究阶段。（图片来源：网络）2022年6月28日，复宏汉霖（2696.HK）与Palleon宣布达成战略合作，共同开发和商业化两款双功能抗体-唾液酸酶融合蛋白。这两款合作产品通过Palleon公司的酶-抗体聚糖配体编辑（Enzyme-Antibody Glyco-Ligand Editing，EAGLE）平台设计，包括一款Palleon的临床前开发阶段的双功能抗HER2抗体-唾液酸酶融合蛋白，以及一款将基于复宏汉霖针对肿瘤相关抗原（TAA）靶点开发的抗体设计的双功能唾液酸酶融合蛋白。据悉，复宏汉霖获得这两款产品在中国（包括港澳台地区）的独家许可；Palleon则保留其他全球区域的权利；Palleon将获得首付款及可达1.965亿美元的里程碑付款。04备受关注的演讲2021年9月23日，药时代推荐分享了Bertozzi教授演讲的报道文章和小视频。受到朋友们的关注，阅读量1.3万+。干货！靶向蛋白降解会议视频记录 | Carolyn Bertozzi点击这里，欣赏诺奖得主Bertozzi教授的精彩演讲！05学霸、摇滚乐队的键盘手、和声我们非常喜欢旧未来OldFuture视频号制作的这个小视频！其中写到：2022诺贝尔化学奖出来以后，大家都被Bertozzi教授迷得不行，「天呐！她怎么那么酷！」说顺便只是开个玩笑，她是诺贝尔百年史上第八位女性诺贝尔化学奖得主，还是重金属乐队的键盘手和和声。父亲是MIT的物理教授，她自己在被哈佛录取后，想要去学音乐。但是因为父母不乐意，所以她的选择路径开始这么各种拐弯。 父母不乐意——ok fine去学医吧——应付必修课太无聊，去学生物吧——wow有机化学这么有趣？——那还学什么生物？学化学吧虽然我们看到了她现在的光鲜亮丽，但是她的化学科研之路也没那么顺利，一开始没有实验室接收她，所以她开启了她的Plan B，想着生物化学或者物理化学是不是也行？从哈佛毕业后，进入UC伯克利，博士毕业后，回到母校出任教职，正是在那里，她开拓了生物正交化学这一全新领域，开辟了全新的天地，让科学家们能在活体生物中研究化学反应如何进行。 尽管选择了化学科研道路，但她从未放弃音乐梦。在哈佛时，她加入了一个非常个性的重金属乐队“bored of education”。她在里面担任键盘手与和声 她的经历总让人想起皇后乐队的吉他手梅校长 同是搞科研的人，一样玩乐队。学霸的才华用到不同领域发着不同的光。参考资料：这些女性诺奖得主既是杰出的科学家，也是成功的企业家！2022年诺奖得主Carolyn Bertozzi教授的精彩演讲！1.3万名同药已观看！~~2022年诺贝尔化学奖得主：利用化学技术颠覆癌症治疗，9月刚与中国公司达成合作诺奖得主创立！这10多家公司正在开发哪些前沿疗法？博士生涯差点腰斩，靠唱摇滚赚生活费……一文了解新晋诺奖得主Carolyn Bertozzi教授诺贝尔化学奖今天揭晓！黎健博士 | 分子海洋钓鲸鲲一一记诺贝尔化学奖得主夏普莱斯（K. Barry Sharpless）教授股票大涨！今年的诺贝尔化学奖得主很年轻，既是杰出的科学家，也是成功的企业家！【视频】明日开奖！2022诺奖得主即将诞生！您赞同徐亦迅博士的预测吗？｜请投票！～黎健博士 | 生子当如布鲁斯！——诺贝尔奖得主Bruce Beutler教授的故事阿维菌素的发现：2015年诺贝尔奖之虚实真假 | 罗伊·瓦杰洛斯博士的礼物那些“荣获” 诺贝尔奖的植物，成为拯救人类的良药2021年诺贝尔化学奖回归化学，授予不对称有机催化领域今天上午9点，徐亦迅博士解读：2021年度诺贝尔生理学或医学奖花落谁家？| 药时代与返朴联合主办专栏 | 化学诗歌总相宜——记诺贝尔化学奖得主、诗人霍夫曼（Roald Hoffmann）教授专栏 | 面壁十年图破壁——诺贝尔化学奖得主埃里克⋅贝齐格（Eric Betzig）博士的传奇故事公司官网其它公开资料封面图来源：网络版权声明/免责声明本文为原创汇编文章，版权归拥有者。仅供感兴趣的个人谨慎参考，非商用，非医用、非投资用。欢迎朋友们批评指正！衷心感谢！文中图片、视频为授权正版作品，或来自微信公共图片库，或取自公司官网/网络根据CC0协议使用，版权归拥有者。任何问题，请与我们联系（电话：13651980212。微信：27674131。邮箱：contact@drugtimes.cn）。衷心感谢！推荐阅读黎健博士 | 分子海洋钓鲸鲲一一记诺贝尔化学奖得主夏普莱斯（K. Barry Sharpless）教授重磅！动物实验不会被禁止！请大家放心！2022年诺奖得主Carolyn Bertozzi教授的精彩演讲！1.3万名同药已观看！~~振奋！港股全面飙涨！康方、和铂、加科思、百济神州、再鼎、欧康维视、荣昌生物、德琪、基石、科济、药明巨诺、诺诚健华、腾盛博药。。。辉瑞1.16亿美元收购！｜手机APP能检测新冠病毒吗？宇宙第一大药厂斥资1.16亿美元寻找答案诺贝尔化学奖今天揭晓！新药IVPP逻辑 | 一个放之四海而皆准的理论？请投票！～「行业大地震」？「天价猴子」要不香了？美国参议院一致通过「终止动物试验授权」的「FDA现代化法案」干货！恒瑞、百济神州等知名药企2022年上半年「研发支出」、「销售费用」简析【视频】明日开奖！2022诺奖得主即将诞生！您赞同徐亦迅博士的预测吗？｜请投票！～上海临床研究中心正式开工！预计2025年底竣工，2026年试运营成功药早，时代要好！药时代敬祝广大朋友们节日快乐！请欣赏优美歌曲和文章！～～健艾仕生物STAT5抑制剂在新冠肺炎引起的炎症因子风暴的临床试验进展顺利卢煜明因无创检测获拉斯克奖，距离诺奖还远吗？卡脖子 or 被卡脖子？生物制药产业供应链「国产替代」，已经需要争分夺秒！三款重磅PARP遇挫，FDA再「出手」，NMPA「如何面对」？刷新OS数据！H药登上JAMA主刊，PD-1治疗小细胞肺癌重大突破！药企的安得广厦千万间肿瘤药全部扑街！FDA两天开了4场专家咨询委员会，竟然只有一款「粪便疗法」通过了...中国制药江湖「神曲」！~~ 继《PD-1之歌》之后，药时代拟推出《双抗之歌》 | 附：30+篇双抗主题好文章行业再现【淘金者】：我就再赌最后一把！三院士齐聚！以临床价值为导向，打造生物医药源头创新机制 | 上海源创新药高峰论坛圆满落幕！阿尔茨海默病，可能是我们老去后的结局……RSV领域时隔60年起风云！阿斯利康/赛诺菲，一剂绝尘！罗永庆离开腾盛博药加盟云顶新耀，中国药企挖人大战进入白热化。这是行业成熟的标志吗？请投票！点击这里，与几百位朋友们欢聚CMC高峰论坛！点击这里，报名参加第三届中国新药CMC高峰论坛！